Software company DocuSign’s (DOCU) stock scored a rating upgrade from Hold to Buy from William Blair, thanks to the optimism ...

Confluent (NASDAQ:CFLT – Get Free Report)‘s stock had its “outperform” rating reissued by analysts at William Blair in a ...

Fintel reports that on March 17, 2025, William Blair upgraded their outlook for DocuSign (NasdaqGS:DOCU) from Market Perform ...

Fintel reports that on March 18, 2025, William Blair downgraded their outlook for Incyte (NasdaqGS:INCY) from Outperform to Market Perform. Analyst Price Forecast Suggests 28.39% Upside As of March 4, ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Analysts at William Blair lowered their Q1 2025 earnings estimates for Legend Biotech in a research report issued to clients ...

In a report released today, Ross Sparenblek from William Blair maintained a Buy rating on MSA Safety (MSA – Research Report). The company’s ...

The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...

We recently published a list of 11 Best Reddit Stocks to Invest In. In this article, we are going to take a look at where ...

Investing.com -- William Blair analysts issued a cautionary note on Palantir Technologies (NASDAQ:PLTR), highlighting potential downside risk for the stock despite continued commercial momentum.

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...